Company intelligence / Profile preview

Gaoyue Group

China

Ownership: Private
Development stage: Other

Overview

Gaoyue Group is the life science infrastructure platform of Hillhouse Capital. It builds and operates a national life science network and a comprehensive 'Lab-to-Market' ecosystem, supporting innovation and commercialization across the life sciences sector in China. Its primary role is to provide infrastructure and ecosystem services rather than engaging in drug discovery or development, and it does not have a clinical pipeline or therapeutic products.

Industry: Investors

Beyond the preview

Go deeper on Gaoyue Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gaoyue Group.

Explore the full profile